Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC
出版年份 2021 全文链接
标题
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC
作者
关键词
-
出版物
Journal of Thoracic Oncology
Volume 16, Issue 4, Pages 528-531
出版商
Elsevier BV
发表日期
2021-03-27
DOI
10.1016/j.jtho.2020.12.022
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
- (2020) Ibiayi Dagogo-Jack et al. CLINICAL CANCER RESEARCH
- Brief report: Preliminary clinical and molecular analysis results from a single arm phase 2 trial of brigatinib in patients with disease progression after next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in advanced ALK + non-small cell lung cancer
- (2020) Thomas E. Stinchcombe et al. Journal of Thoracic Oncology
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study
- (2019) D. Ross Camidge et al. Journal of Thoracic Oncology
- Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
- (2019) Kazuhiko Nakagawa et al. LUNG CANCER
- Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung
- (2018) Sinead A. Noonan et al. Journal of Thoracic Oncology
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor
- (2018) Terry L. Ng et al. LUNG CANCER
- Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer
- (2018) Jose M. Pacheco et al. Journal of Thoracic Oncology
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases
- (2016) Paul D. Brown et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib
- (2014) Gregory N. Gan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
- (2012) Andrew J. Weickhardt et al. Journal of Thoracic Oncology
- Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
- (2011) D. Ross Camidge et al. Journal of Thoracic Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now